Additional information
| Active substance | Pioglitazone |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | Monitoring blood glucose and liver function tests |
| Also known as | Pioglitazone hydrochloride |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Could potentially cause fluid retention which might increase blood pressure |
| Trade name | Actos |
| Storage conditions | Store at room temperature, protect from moisture and light |
| Chemical name | 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| Formula | C19H20N2O3S |
| Substance class | Thiazolidinedione |
| Main action | Antidiabetic, insulin sensitizer |
| Half-life | 3-7 hours |
| Dosage (medical) | Typically 15-45 mg per day |
| Dosage (sports) | Not applicable |
| Effects | Lowers blood glucose, increases insulin sensitivity |
| Side effects | Weight gain, edema, heart failure, increased risk of bladder cancer, bone fractures |
| Use in sports | Not typically used in sports |
| Manufacturer | Takeda |

EPO 3000iu GENERIC
Seretide Disckus (Advair) 500 mcg Glaxosmithkline
Clenbuterolhydrochlorid Sopharma
FUCIDIN 500 mg Abdi Ibragim
BIOSYNERGY RECOVERY3 PEPTIDE BLEND LIFETECH LABS
Clexane 0.4 Sanofi
Champix 56 tabs Pfizer
CANTAB PLUS 32/12.5 mg Nobel
Triptorelin 2mg GENERIC
Rovamycine 3.000.000 iu Eczacibasi 

Reviews
There are no reviews yet.